Primary outcome
What NCT05786521 measured first
| Semaglutide and Lifestyle Interventionn=10 | Lifestyle Interventionn=10 |
|---|---|
| -1730.6(-3063 to -398) | -421(-1745 to 911) |
Phase 4 · Semaglutide
NCT05786521 trial results
The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance
Lean Body Mass Change (g), Baseline to 20 weeks. Semaglutide and Lifestyle Intervention: -1730.6; Lifestyle Intervention: -421.
- Participants
- 20
- Status
- completed
- Completed
- 2024-05-20
- Sponsor
- The University of Texas Health Science Center at San Antonio
As posted on ClinicalTrials.gov (NCT05786521), updated at source May 4, 2025. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
Side effects by arm
Side effects in NCT05786521
Percent of participants affected, 20 weeks. The most common events the registry lists.
| Event | Semaglutide and Lifestyle Intervention | Lifestyle Intervention |
|---|---|---|
| Any serious event | 0% | 0% |
| Abdominal pain | 60% | 10% |
The trial
How NCT05786521 was run
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
- Semaglutide and lifestyle intervention: Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
- Lifestyle intervention: Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program
Who could join the trial
Inclusion Criteria: * Older than 65 * Have prediabetes or diabetes * BMI ≥ 27.0 kg/m2 * Living independently (not in assisted living or nursing home) Exclusion Criteria: * Have heart disease * Have liver disease * Smoke
Published papers
Papers from NCT05786521
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.